- Home
- KZR vs SNY Comparison
KZR vs SNY Comparison
Compare KZR & SNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KZR
- SNY
- Stock Information
- Founded
- KZR 2015
- SNY 1994
- Country
- KZR United States
- SNY France
- Employees
- KZR N/A
- SNY N/A
- Industry
- KZR Biotechnology: Pharmaceutical Preparations
- SNY Biotechnology: Pharmaceutical Preparations
- Sector
- KZR Health Care
- SNY Health Care
- Exchange
- KZR Nasdaq
- SNY Nasdaq
- Market Cap
- KZR 29.7M
- SNY 113.4B
- IPO Year
- KZR 2018
- SNY N/A
- Fundamental
- Price
- KZR $3.91
- SNY $46.61
- Analyst Decision
- KZR Hold
- SNY Buy
- Analyst Count
- KZR 2
- SNY 4
- Target Price
- KZR $9.00
- SNY $61.50
- AVG Volume (30 Days)
- KZR 34.3K
- SNY 2.8M
- Earning Date
- KZR 11-11-2025
- SNY 10-24-2025
- Dividend Yield
- KZR N/A
- SNY 3.43%
- EPS Growth
- KZR N/A
- SNY 118.56
- EPS
- KZR N/A
- SNY 8.65
- Revenue
- KZR N/A
- SNY $53,714,621,258.00
- Revenue This Year
- KZR N/A
- SNY $1.53
- Revenue Next Year
- KZR N/A
- SNY $7.06
- P/E Ratio
- KZR N/A
- SNY $5.39
- Revenue Growth
- KZR N/A
- SNY 15.65
- 52 Week Low
- KZR $3.62
- SNY $44.73
- 52 Week High
- KZR $9.18
- SNY $60.12
- Technical
- Relative Strength Index (RSI)
- KZR 43.94
- SNY 40.69
- Support Level
- KZR $3.76
- SNY $46.79
- Resistance Level
- KZR $4.09
- SNY $47.69
- Average True Range (ATR)
- KZR 0.14
- SNY 0.68
- MACD
- KZR 0.01
- SNY -0.26
- Stochastic Oscillator
- KZR 38.46
- SNY 27.40
About KZR Kezar Life Sciences Inc.
Kezar Life Sciences Inc is a clinical-stage biotechnology company. It is engaged in discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer. The pipeline consist of product candidates such as Zetomipzomib (KZR-616), and KZR-261.
About SNY Sanofi ADS
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for approximately 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.